Civitas Announces Positive Results from Phase II Inhaled Levodopa Trial

Civitas Therapeutics announced that its inhaled formulation of levodopa (L-dopa) for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial. Read more…